R01HD105868
Project Grant
Overview
Grant Description
Genomics and Functional Dissection of Fetal Brain Abnormalities Using a Prenatal Cohort - Abstract
Fetal brain abnormalities (FBA) are one of the most common prenatal sonographic abnormalities detected and account for approximately 20% of birth defects, posing a substantial burden on the healthcare system. FBA can be isolated or syndromic and exhibit vast phenotypic heterogeneity. The paired approach of prenatal diagnosis, using ultrasound to characterize aberrant phenotypes, along with genetic analysis to determine causal lesions, has improved the ability to accurately counsel families about diagnosis, prognosis, and recurrence risk.
Recently, prenatal exome sequencing (ES) has been applied in cases of lethal or multiple fetal abnormalities to determine a molecular diagnosis that otherwise could not be identified with traditional testing. Our group, along with others using ES, has shown a diagnostic rate of 23.6% in cases of multiple fetal abnormalities, but only 2.6% in isolated FBA abnormalities. This indicates a need to improve diagnostic capabilities for FBA.
We posit that the overabundance of unresolved fetal cases is due to a gap in our understanding of the repertoire of genotypes underlying prenatal FBA and limitations of population genetics to establish causality of rare variants in novel candidate genes. Our team, at the forefront of prenatal genetic diagnostics and in vivo zebrafish modeling of human disease, will overcome the current challenges of diagnosing prenatal FBA. We will intersect exome- and genome-wide variation with a relevant model system (zebrafish).
We hypothesize that we will:
1) Generate initial discoveries directly relevant to human brain development by modeling novel candidate FBA genes in zebrafish; and
2) Improve prenatal diagnosis for FBA using whole genome sequencing (WGS) and deep phenotyping.
To achieve this, we will:
1. Perform bioinformatic analysis of 200+ clinically ascertained fetuses with FBA and their parents using a tiered filtering strategy on already available parent-fetus trio exome data.
2. Perform WGS on 114 prospectively enrolled fetuses and their parents, paired with comprehensive prenatal and postnatal phenotypic data, to further characterize genotype/phenotype of FBA.
3. Establish the relevance of candidate genes to FBA development and determine variant pathogenicity using genome-editing and phenotyping tools in zebrafish.
Our work will expand the understanding of molecular processes governing human brain development, establish a clinical-research hybrid platform readily applicable to FBA and other anatomical defects detectable by fetal imaging, build an animal model of aberrant FBA development with potential for future use in therapeutic target identification. Our immediate results will improve counseling/management of prenatally diagnosed FBA and lead to future work to develop novel therapeutic and preventative strategies for FBA.
Fetal brain abnormalities (FBA) are one of the most common prenatal sonographic abnormalities detected and account for approximately 20% of birth defects, posing a substantial burden on the healthcare system. FBA can be isolated or syndromic and exhibit vast phenotypic heterogeneity. The paired approach of prenatal diagnosis, using ultrasound to characterize aberrant phenotypes, along with genetic analysis to determine causal lesions, has improved the ability to accurately counsel families about diagnosis, prognosis, and recurrence risk.
Recently, prenatal exome sequencing (ES) has been applied in cases of lethal or multiple fetal abnormalities to determine a molecular diagnosis that otherwise could not be identified with traditional testing. Our group, along with others using ES, has shown a diagnostic rate of 23.6% in cases of multiple fetal abnormalities, but only 2.6% in isolated FBA abnormalities. This indicates a need to improve diagnostic capabilities for FBA.
We posit that the overabundance of unresolved fetal cases is due to a gap in our understanding of the repertoire of genotypes underlying prenatal FBA and limitations of population genetics to establish causality of rare variants in novel candidate genes. Our team, at the forefront of prenatal genetic diagnostics and in vivo zebrafish modeling of human disease, will overcome the current challenges of diagnosing prenatal FBA. We will intersect exome- and genome-wide variation with a relevant model system (zebrafish).
We hypothesize that we will:
1) Generate initial discoveries directly relevant to human brain development by modeling novel candidate FBA genes in zebrafish; and
2) Improve prenatal diagnosis for FBA using whole genome sequencing (WGS) and deep phenotyping.
To achieve this, we will:
1. Perform bioinformatic analysis of 200+ clinically ascertained fetuses with FBA and their parents using a tiered filtering strategy on already available parent-fetus trio exome data.
2. Perform WGS on 114 prospectively enrolled fetuses and their parents, paired with comprehensive prenatal and postnatal phenotypic data, to further characterize genotype/phenotype of FBA.
3. Establish the relevance of candidate genes to FBA development and determine variant pathogenicity using genome-editing and phenotyping tools in zebrafish.
Our work will expand the understanding of molecular processes governing human brain development, establish a clinical-research hybrid platform readily applicable to FBA and other anatomical defects detectable by fetal imaging, build an animal model of aberrant FBA development with potential for future use in therapeutic target identification. Our immediate results will improve counseling/management of prenatally diagnosed FBA and lead to future work to develop novel therapeutic and preventative strategies for FBA.
Funding Goals
TO CONDUCT AND SUPPORT LABORATORY RESEARCH, CLINICAL TRIALS, AND STUDIES WITH PEOPLE THAT EXPLORE HEALTH PROCESSES. NICHD RESEARCHERS EXAMINE GROWTH AND DEVELOPMENT, BIOLOGIC AND REPRODUCTIVE FUNCTIONS, BEHAVIOR PATTERNS, AND POPULATION DYNAMICS TO PROTECT AND MAINTAIN THE HEALTH OF ALL PEOPLE. TO EXAMINE THE IMPACT OF DISABILITIES, DISEASES, AND DEFECTS ON THE LIVES OF INDIVIDUALS. WITH THIS INFORMATION, THE NICHD HOPES TO RESTORE, INCREASE, AND MAXIMIZE THE CAPABILITIES OF PEOPLE AFFECTED BY DISEASE AND INJURY. TO SPONSOR TRAINING PROGRAMS FOR SCIENTISTS, DOCTORS, AND RESEARCHERS TO ENSURE THAT NICHD RESEARCH CAN CONTINUE. BY TRAINING THESE PROFESSIONALS IN THE LATEST RESEARCH METHODS AND TECHNOLOGIES, THE NICHD WILL BE ABLE TO CONDUCT ITS RESEARCH AND MAKE HEALTH RESEARCH PROGRESS UNTIL ALL CHILDREN, ADULTS, FAMILIES, AND POPULATIONS ENJOY GOOD HEALTH. THE MISSION OF THE NICHD IS TO ENSURE THAT EVERY PERSON IS BORN HEALTHY AND WANTED, THAT WOMEN SUFFER NO HARMFUL EFFECTS FROM REPRODUCTIVE PROCESSES, AND THAT ALL CHILDREN HAVE THE CHANCE TO ACHIEVE THEIR FULL POTENTIAL FOR HEALTHY AND PRODUCTIVE LIVES, FREE FROM DISEASE OR DISABILITY, AND TO ENSURE THE HEALTH, PRODUCTIVITY, INDEPENDENCE, AND WELL-BEING OF ALL PEOPLE THROUGH OPTIMAL REHABILITATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Chapel Hill,
North Carolina
27599
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 401% from $680,066 to $3,407,070.
University Of North Carolina At Chapel Hill was awarded
Prenatal Genomics for Fetal Brain Abnormalities
Project Grant R01HD105868
worth $3,407,070
from the National Institute of Child Health and Human Development in August 2021 with work to be completed primarily in Chapel Hill North Carolina United States.
The grant
has a duration of 4 years 10 months and
was awarded through assistance program 93.865 Child Health and Human Development Extramural Research.
The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 8/20/25
Period of Performance
8/12/21
Start Date
6/30/26
End Date
Funding Split
$3.4M
Federal Obligation
$0.0
Non-Federal Obligation
$3.4M
Total Obligated
Activity Timeline
Transaction History
Modifications to R01HD105868
Additional Detail
Award ID FAIN
R01HD105868
SAI Number
R01HD105868-3805025165
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NT00 NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development
Funding Office
75NT00 NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development
Awardee UEI
D3LHU66KBLD5
Awardee CAGE
4B856
Performance District
NC-04
Senators
Thom Tillis
Ted Budd
Ted Budd
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Institute of Child Health and Human Development, National Institutes of Health, Health and Human Services (075-0844) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,306,993 | 89% |
Office of the Director, National Institutes of Health, Health and Human Services (075-0846) | Health research and training | Grants, subsidies, and contributions (41.0) | $155,500 | 11% |
Modified: 8/20/25